Table 1.
Clinical characteristicsa of the Malmö Diet and Cancer Study participants at baseline examination (1991–1996) according to the quartiles of suPAR
| N | All | Q1 | Q2 | Q3 | Q4 | P valueb | |
|---|---|---|---|---|---|---|---|
| Mean (range) suPAR (ng/ml) | 5135 | 3.0 (0.0–35.9) | 2.1 (0.0–2.4) | 2.6 (2.4–2.8) | 3.1 (2.8–3.4) | 4.4 (3.4–35.9) | <0.001 |
| Age (yr) | 5135 | 57.6 (5.9) | 55.7 (5.7) | 57.34 (5.9) | 58.7 (5.7) | 58.8 (5.9) | <0.001 |
| Male sex, n (%) | 5135 | 2114 (41.2%) | 642 (50.0%) | 551 (42.9%) | 450 (35.1%) | 471 (36.7%) | <0.001 |
| Height (cm) | 5135 | 169 (8.9) | 171 (9.04) | 169 (8.9) | 168 (8.83) | 168 (8.7) | 0.04 |
| Weight (kg) | 5135 | 74 (13.6) | 73 (13.09) | 73 (12.63) | 74 (13.87) | 74 (14.59) | <0.001 |
| BMI (kg/m2) | 5135 | 25.7 (3.9) | 25.1 (3.4) | 25.5 (3.6) | 26.0 (4.0) | 26.2 (4.6) | <0.001 |
| SBP (mm Hg) | 5135 | 142 (19.0) | 138 (17.2) | 141 (18.8) | 143 (19.6) | 144 (19.9) | <0.001 |
| DBP (mm Hg) | 5135 | 87 (9.3) | 86 (8.7) | 87 (9.5) | 87 (9.5) | 87 (9.7) | 0.028 |
| Waist (cm) | 5134 | 83.8 (12.9) | 83.2 (12.5) | 83.3 (12.5) | 83.7 (13.0) | 84.9 (13.6) | <0.001 |
| Fasting glucose (mmol/l) | 5135 | 5.2 (1.4) | 5.0 (0.8) | 5.1 (1.2) | 5.2 (1.4) | 5.4 (1.9) | <0.001 |
| Cystatin C (mg/l) | 4814 | 0.8 (0.2) | 0.7 (0.1) | 0.8 (0.1) | 0.8 (0.1) | 0.9 (0.2) | <0.001 |
| P-Creatinine (μmol/l) | 5135 | 84.8 (16.4) | 85.3 (14.6) | 85.4 (14.4) | 83.6 (15.0) | 85.0 (20.5) | 0.829 |
| eGFR (ml/min per 1.73 m2) | 5135 | 76.0 (13.7) | 78.1 (13.3) | 75.7 (13.1) | 75.3 (13.4) | 75.1 (14.9) | 0.145 |
| AHT, n (%) | 5135 | 889 (17.8%) | 166 (12.9%) | 196 (15.3%) | 252 (19.6%) | 275 (21.4%) | <0.001 |
| Current smoking, n (%) | 5135 | 1377 (26.8%) | 192 (15.0%) | 226 (17.6%) | 316 (24.6%) | 643 (50.1%) | <0.001 |
AHT, antihypertensive treatment; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate according to the Chronic Kidney Disease Epidemiology Collaboration creatinine equation23; SBP, systolic blood pressure; suPAR, soluble urokinase-type plasminogen activator receptor.
a
Data shown as mean ± SD or n (%).
b
P value adjusted for age and sex, or χ2 (1df) test (categorical variables).